PMID- 34358149
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210809
IS  - 2076-393X (Print)
IS  - 2076-393X (Electronic)
IS  - 2076-393X (Linking)
VI  - 9
IP  - 7
DP  - 2021 Jul 2
TI  - Fusion Protein of Rotavirus VP6 and SARS-CoV-2 Receptor Binding Domain Induces T 
      Cell Responses.
LID - 10.3390/vaccines9070733 [doi]
LID - 733
AB  - Vaccines based on mRNA and viral vectors are currently used in the frontline to 
      combat the ongoing pandemic caused by the novel Severe Acute Respiratory Syndrome 
      Coronavirus-2 (SARS-CoV-2). However, there is still an urgent need for 
      alternative vaccine technologies inducing/boosting long-lasting and 
      cross-reactive immunity in different populations. As a possible vaccine 
      candidate, we employed the rotavirus VP6-protein platform to construct a fusion 
      protein (FP) displaying receptor-binding domain (RBD) of SARS-CoV-2 spike protein 
      (S) at the N-terminus of VP6. The recombinant baculovirus-insect cell produced 
      VP6-RBD FP was proven antigenic in vitro and bound to the human 
      angiotensin-converting enzyme 2 (hACE2) receptor. The FP was used to immunize 
      BALB/c mice, and humoral- and T cell-mediated immune responses were investigated. 
      SARS-CoV-2 RBD-specific T cells were induced at a high quantity; however, no RBD 
      or S-specific antibodies were detected. The results suggest that conformational B 
      cell epitopes might be buried inside the VP6, while RBD-specific T cell epitopes 
      are available for T cell recognition after the processing and presentation of FP 
      by the antigen-presenting cells. Further immunogenicity studies are needed to 
      confirm these findings and to assess whether, under different experimental 
      conditions, the VP6 platform may present SARS-CoV-2 antigens to B cells as well.
FAU - Tamminen, Kirsi
AU  - Tamminen K
AUID- ORCID: 0000-0002-9708-732X
AD  - Vaccine Development and Immunology/Vaccine Research Center, Faculty of Medicine 
      and Health Technology, Tampere University, Arvo Ylpon katu 34, FI-33520 Tampere, 
      Finland.
FAU - Heinimaki, Suvi
AU  - Heinimaki S
AUID- ORCID: 0000-0001-9374-4583
AD  - Vaccine Development and Immunology/Vaccine Research Center, Faculty of Medicine 
      and Health Technology, Tampere University, Arvo Ylpon katu 34, FI-33520 Tampere, 
      Finland.
FAU - Grohn, Stina
AU  - Grohn S
AD  - Vaccine Development and Immunology/Vaccine Research Center, Faculty of Medicine 
      and Health Technology, Tampere University, Arvo Ylpon katu 34, FI-33520 Tampere, 
      Finland.
FAU - Blazevic, Vesna
AU  - Blazevic V
AUID- ORCID: 0000-0001-8201-6118
AD  - Vaccine Development and Immunology/Vaccine Research Center, Faculty of Medicine 
      and Health Technology, Tampere University, Arvo Ylpon katu 34, FI-33520 Tampere, 
      Finland.
LA  - eng
GR  - Immunoexellence project under Profi4 program/Academy of Finland/
PT  - Journal Article
DEP - 20210702
PL  - Switzerland
TA  - Vaccines (Basel)
JT  - Vaccines
JID - 101629355
PMC - PMC8309989
OTO - NOTNLM
OT  - COVID-19
OT  - SARS-CoV-2
OT  - T cells
OT  - VP6
OT  - antibodies
OT  - delivery platform
OT  - immune response
OT  - vaccines
COIS- The authors declare no conflict of interest.
EDAT- 2021/08/07 06:00
MHDA- 2021/08/07 06:01
PMCR- 2021/07/02
CRDT- 2021/08/06 17:18
PHST- 2021/05/25 00:00 [received]
PHST- 2021/06/14 00:00 [revised]
PHST- 2021/06/21 00:00 [accepted]
PHST- 2021/08/06 17:18 [entrez]
PHST- 2021/08/07 06:00 [pubmed]
PHST- 2021/08/07 06:01 [medline]
PHST- 2021/07/02 00:00 [pmc-release]
AID - vaccines9070733 [pii]
AID - vaccines-09-00733 [pii]
AID - 10.3390/vaccines9070733 [doi]
PST - epublish
SO  - Vaccines (Basel). 2021 Jul 2;9(7):733. doi: 10.3390/vaccines9070733.